299 related articles for article (PubMed ID: 15458443)
1. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats.
Fujisawa G; Okada K; Muto S; Fujita N; Itabashi N; Kusano E; Ishibashi S
Kidney Int; 2004 Oct; 66(4):1493-502. PubMed ID: 15458443
[TBL] [Abstract][Full Text] [Related]
2. Spironolactone exhibits direct renoprotective effects and inhibits renal renin-angiotensin-aldosterone system in diabetic rats.
Taira M; Toba H; Murakami M; Iga I; Serizawa R; Murata S; Kobara M; Nakata T
Eur J Pharmacol; 2008 Jul; 589(1-3):264-71. PubMed ID: 18582458
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effects of spironolactone on glomerular injury in streptozotocin-induced diabetic rats.
Yuan J; Jia R; Bao Y
J Renin Angiotensin Aldosterone Syst; 2007 Sep; 8(3):118-26. PubMed ID: 17907099
[TBL] [Abstract][Full Text] [Related]
4. Reactive oxygen species mediate high glucose-induced plasminogen activator inhibitor-1 up-regulation in mesangial cells and in diabetic kidney.
Lee EA; Seo JY; Jiang Z; Yu MR; Kwon MK; Ha H; Lee HB
Kidney Int; 2005 May; 67(5):1762-71. PubMed ID: 15840023
[TBL] [Abstract][Full Text] [Related]
5. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats.
Miric G; Dallemagne C; Endre Z; Margolin S; Taylor SM; Brown L
Br J Pharmacol; 2001 Jul; 133(5):687-94. PubMed ID: 11429393
[TBL] [Abstract][Full Text] [Related]
6. Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus.
Guo C; Martinez-Vasquez D; Mendez GP; Toniolo MF; Yao TM; Oestreicher EM; Kikuchi T; Lapointe N; Pojoga L; Williams GH; Ricchiuti V; Adler GK
Endocrinology; 2006 Nov; 147(11):5363-73. PubMed ID: 16901964
[TBL] [Abstract][Full Text] [Related]
7. [Effect of selective cyclooxygenase -2 inhibitor on the renal lesion of streptozotocin-induced diabetic rats and its possible mechanism].
Zuo Y; Gu Y; Ma J; Lin S
Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(4):239-43. PubMed ID: 11953170
[TBL] [Abstract][Full Text] [Related]
8. Prevention of early renal injury by mycophenolate mofetil and its mechanism in experimental diabetes.
Wu YG; Lin H; Qi XM; Wu GZ; Qian H; Zhao M; Shen JJ; Lin ST
Int Immunopharmacol; 2006 Mar; 6(3):445-53. PubMed ID: 16428080
[TBL] [Abstract][Full Text] [Related]
9. RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
Koszegi S; Molnar A; Lenart L; Hodrea J; Balogh DB; Lakat T; Szkibinszkij E; Hosszu A; Sparding N; Genovese F; Wagner L; Vannay A; Szabo AJ; Fekete A
J Physiol; 2019 Jan; 597(1):193-209. PubMed ID: 30324679
[TBL] [Abstract][Full Text] [Related]
10. Effect of eplerenone, enalapril and their combination treatment on diabetic nephropathy in type II diabetic rats.
Kang YS; Ko GJ; Lee MH; Song HK; Han SY; Han KH; Kim HK; Han JY; Cha DR
Nephrol Dial Transplant; 2009 Jan; 24(1):73-84. PubMed ID: 18682491
[TBL] [Abstract][Full Text] [Related]
11. Norcantharidin attenuates tubulointerstitial fibrosis in rat models with diabetic nephropathy.
Li Y; Chen Q; Liu FY; Peng YM; Hou T; Duan SB; Li J; Luo JH; Sun L; Ling GH
Ren Fail; 2011; 33(2):233-41. PubMed ID: 21332346
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of local aldosterone by eplerenone reduces renal structural damage in a novel model of chronic cyclosporine A nephrotoxicity.
Sun QL; Li M; Rui HL; Chen YP
J Renin Angiotensin Aldosterone Syst; 2015 Jun; 16(2):301-10. PubMed ID: 25500744
[TBL] [Abstract][Full Text] [Related]
13. Long-term mineralocorticoid receptor blockade ameliorates progression of experimental diabetic renal disease.
Lian M; Hewitson TD; Wigg B; Samuel CS; Chow F; Becker GJ
Nephrol Dial Transplant; 2012 Mar; 27(3):906-12. PubMed ID: 21908416
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy with spironolactone and candesartan protects against streptozotocin-induced diabetic nephropathy in rats.
Hofni A; El-Moselhy MA; Taye A; Khalifa MM
Eur J Pharmacol; 2014 Dec; 744():173-82. PubMed ID: 25446917
[TBL] [Abstract][Full Text] [Related]
15. Acetylshikonin from Zicao ameliorates renal dysfunction and fibrosis in diabetic mice by inhibiting TGF-β1/Smad pathway.
Li Z; Hong Z; Peng Z; Zhao Y; Shao R
Hum Cell; 2018 Jul; 31(3):199-209. PubMed ID: 29549584
[TBL] [Abstract][Full Text] [Related]
16. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
Noh H; Oh EY; Seo JY; Yu MR; Kim YO; Ha H; Lee HB
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F729-39. PubMed ID: 19553350
[TBL] [Abstract][Full Text] [Related]
17. Effects of Bone Marrow Mesenchymal Stem Cells on Plasminogen Activator Inhibitor-1 and Renal Fibrosis in Rats with Diabetic Nephropathy.
Lang H; Dai C
Arch Med Res; 2016 Feb; 47(2):71-7. PubMed ID: 27018336
[TBL] [Abstract][Full Text] [Related]
18. Selenium-deficient diet induces renal oxidative stress and injury via TGF-beta1 in normal and diabetic rats.
Reddi AS; Bollineni JS
Kidney Int; 2001 Apr; 59(4):1342-53. PubMed ID: 11260395
[TBL] [Abstract][Full Text] [Related]
19. Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.
Qin J; Zhang Z; Liu J; Sun L; Hu L; Cooper ME; Cao Z
Kidney Int; 2003 Aug; 64(2):565-71. PubMed ID: 12846751
[TBL] [Abstract][Full Text] [Related]
20. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo.
Brown NJ; Nakamura S; Ma L; Nakamura I; Donnert E; Freeman M; Vaughan DE; Fogo AB
Kidney Int; 2000 Sep; 58(3):1219-27. PubMed ID: 10972684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
